<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03489343</url>
  </required_header>
  <id_info>
    <org_study_id>Sym023-01</org_study_id>
    <nct_id>NCT03489343</nct_id>
  </id_info>
  <brief_title>Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas</brief_title>
  <official_title>A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Symphogen A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Symphogen A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was the first study to test Sym023 in humans. The primary purpose of this study was to&#xD;
      see if Sym023 is safe and tolerable for patients with locally advanced/unresectable or&#xD;
      metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or&#xD;
      for which no standard therapy is available.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluated the preliminary safety, tolerability, and dose-limiting toxicities&#xD;
      (DLTs) of Sym023, a recombinant, fully human, anti-T-cell immunoglobulin and mucin-domain&#xD;
      containing-3 (anti-TIM-3) monoclonal antibody (mAb). The goal was to establish the maximum&#xD;
      tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of&#xD;
      Sym023 when administered once every 2 weeks (Q2W) by intravenous (IV) infusion to patient&#xD;
      cohorts with locally advanced/unresectable or metastatic solid tumor malignancies or&#xD;
      lymphomas that are refractory to available therapy or for which no standard therapy is&#xD;
      available. If an MTD was not identified, a maximum administered dose (MAD) was to be&#xD;
      determined. Sym023 was given to patients in escalating dose cohorts; each patient was given&#xD;
      one fixed dose level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2018</start_date>
  <completion_date type="Actual">June 3, 2020</completion_date>
  <primary_completion_date type="Actual">June 3, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Treatment Emergent Adverse Events (AEs) Meeting Dose-limiting Toxicity (DLT) Criteria.</measure>
    <time_frame>28 days</time_frame>
    <description>Assess the safety and tolerability of Sym023 on a Q2W (once every 2 weeks) schedule to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1. The MTD was to be determined by those DLTs that occurred during C1 in either more than 1 patient in a 3 to 6 patient cohort or ≥33.3% of patients in the event of an expanded 7 to 12 patient cohort. One patient in the 10.0 mg/kg dose cohort was not evaluable for MTD as she did not complete C1 for a reason other than drug toxicity (i.e., discontinuation after 1 dose due to patient withdrawal of consent). However, this patient was included in the evaluation of other outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Immunogenicity of Sym023.</measure>
    <time_frame>Baseline up to 6-months follow-up, approximately 1 year</time_frame>
    <description>Serum sampling to assess the potential for anti-drug antibody (ADA) formation. The number of patients with positive samples at indicated visits is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Objective Response (OR) or Stable Disease (SD) by RECIST v1.1</measure>
    <time_frame>24 months</time_frame>
    <description>OR or SD Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). The number of patients with confirmed or unconfirmed OR (partial or complete response) is presented. Duration of SD for patients with best overall response = SD was defined as the time from the day of first study treatment to the start of radiologic disease progression or death. If the patient did not have a radiological disease progression or death, the duration of SD was defined as the time from the day of first study treatment to the date of the last SD assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Objective Response (OR) or Stable Disease (SD) by iRECIST</measure>
    <time_frame>24 months</time_frame>
    <description>OR or SD Assessed by Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST). The number of patients with confirmed or unconfirmed OR (partial or complete response) is presented. Duration of SD for patients with best overall response = SD was defined as the time from the day of first study treatment to the start of radiologic disease progression or death. If the patient did not have a radiological disease progression or death, the duration of SD was defined as the time from the day of first study treatment to the date of the last SD assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Objective Response (OR) or Stable Disease (SD) by RECIL 2017.</measure>
    <time_frame>24 months</time_frame>
    <description>OR or SD Assessed by Response Evaluation Criteria in Lymphomas 2017 (RECIL 2017)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP) of Disease.</measure>
    <time_frame>24 months</time_frame>
    <description>Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1, RECIL 2017, or iRECIST, depending on tumor type. The numbers shown below correspond to the values related to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve in a Dosing Interval (AUC).</measure>
    <time_frame>From before the start of the infusion to 168 hours after the end of the infusion</time_frame>
    <description>The AUC after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax)</measure>
    <time_frame>From before the start of the infusion to 168 hours after the end of the infusion</time_frame>
    <description>Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax)</measure>
    <time_frame>From before the start of the infusion to 168 hours after the end of the infusion</time_frame>
    <description>Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration (Ctrough)</measure>
    <time_frame>From before the start of the infusion to 168 hours after the end of the infusion</time_frame>
    <description>Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (T½)</measure>
    <time_frame>From before the start of the infusion to 168 hours after the end of the infusion</time_frame>
    <description>Outcome measure after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>From before the start of the infusion to 168 hours after the end of the infusion</time_frame>
    <description>Outcome measure after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Solid Tumor</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Sym023 0.03 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sym023 was administered at a dose of 0.03 mg/kg by intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym023 0.1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sym023 was administered at a dose of 0.1 mg/kg by intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym023 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sym023 was administered at a dose of 0.3 mg/kg by intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym023 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sym023 was administered at a dose of 1.0 mg/kg by intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym023 3.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sym023 was administered at a dose of 3.0 mg/kg by intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym023 10.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sym023 was administered at a dose of 10.0 mg/kg by intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym023 20.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sym023 was administered at a dose of 20.0 mg/kg by intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sym023</intervention_name>
    <description>Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.</description>
    <arm_group_label>Sym023 0.03 mg/kg</arm_group_label>
    <arm_group_label>Sym023 0.1 mg/kg</arm_group_label>
    <arm_group_label>Sym023 0.3 mg/kg</arm_group_label>
    <arm_group_label>Sym023 1.0 mg/kg</arm_group_label>
    <arm_group_label>Sym023 10.0 mg/kg</arm_group_label>
    <arm_group_label>Sym023 20.0 mg/kg</arm_group_label>
    <arm_group_label>Sym023 3.0 mg/kg</arm_group_label>
    <other_name>Anti-TIM-3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, ≥ 18 years of age at the time of obtaining informed consent.&#xD;
&#xD;
          -  Documented (histologically- or cytologically-proven) solid tumor malignancy that is&#xD;
             locally advanced or metastatic; patients with documented lymphomas.&#xD;
&#xD;
          -  Malignancy (solid tumor or lymphoma) that is currently not amenable to surgical&#xD;
             intervention due to either medical contraindications or nonresectability of the tumor.&#xD;
&#xD;
          -  Refractory to or intolerant of existing therapy(ies) known to provide clinical&#xD;
             benefit.&#xD;
&#xD;
          -  Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.&#xD;
&#xD;
          -  Not of childbearing potential or who agree to use a highly effective method of&#xD;
             contraception during the study beginning within 2 weeks prior to the first dose and&#xD;
             continuing until 6 months after the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or lactating, or intending to become pregnant before, during,&#xD;
             or within 6 months after the last dose of study drug. Women of childbearing potential&#xD;
             (WOCBP) and fertile men with WOCBP-partner(s) not using and not willing to use a&#xD;
             highly effective method of contraception.&#xD;
&#xD;
          -  Known, untreated central nervous system (CNS) or leptomeningeal metastases, or spinal&#xD;
             cord compression, patients with any of the above not controlled by prior surgery or&#xD;
             radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment&#xD;
             is required.&#xD;
&#xD;
          -  Hematologic malignancies other than lymphomas.&#xD;
&#xD;
          -  Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism&#xD;
             (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and&#xD;
             considered stable.&#xD;
&#xD;
          -  Active uncontrolled bleeding or a known bleeding diathesis.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease or condition.&#xD;
&#xD;
          -  Significant ocular disease or condition, including history of autoimmune or&#xD;
             inflammatory disorder.&#xD;
&#xD;
          -  Significant pulmonary disease or condition.&#xD;
&#xD;
          -  Current or recent (within 6 months) significant gastrointestinal (GI) disease or&#xD;
             condition.&#xD;
&#xD;
          -  An active, known, or suspected autoimmune disease, or a documented history of&#xD;
             autoimmune disease or syndrome, requiring systemic steroids or other immunosuppressive&#xD;
             medications.&#xD;
&#xD;
          -  History of significant toxicities associated with previous administration of immune&#xD;
             checkpoint inhibitors that necessitated permanent discontinuation of that therapy.&#xD;
&#xD;
          -  Patients with unresolved &gt; Grade 1 toxicity associated with any prior antineoplastic&#xD;
             therapy, with exceptions.&#xD;
&#xD;
          -  Inadequate recovery from any prior surgical procedure, or having undergone any major&#xD;
             surgical procedure within 4 weeks prior to C1/D1.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) or known active infection with&#xD;
             hepatitis B virus (HBV) or hepatitis C virus (HCV).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lillian Siu, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics (START) Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <results_first_submitted>April 27, 2021</results_first_submitted>
  <results_first_submitted_qc>October 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2021</results_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced/unresectable</keyword>
  <keyword>Metastatic solid tumor</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Anti-TIM-3</keyword>
  <keyword>TIM-3</keyword>
  <keyword>TIM3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03489343/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 26, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03489343/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sym023 0.03 mg/kg</title>
          <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Sym023 0.1 mg/kg</title>
          <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="P3">
          <title>Sym023 0.3 mg/kg</title>
          <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="P4">
          <title>Sym023 1.0 mg/kg</title>
          <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="P5">
          <title>Sym023 3.0 mg/kg</title>
          <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="P6">
          <title>Sym023 10.0 mg/kg</title>
          <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="P7">
          <title>Sym023 20.0 mg/kg</title>
          <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Documented progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The full analysis set (FAS) comprised all consented patients who had received at least a fraction of 1 dose of study drug. The patients in the FAS contributed to the analyses as allocated to treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Sym023 0.03 mg/kg</title>
          <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Sym023 0.1 mg/kg</title>
          <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Sym023 0.3 mg/kg</title>
          <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="B4">
          <title>Sym023 1.0 mg/kg</title>
          <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="B5">
          <title>Sym023 3.0 mg/kg</title>
          <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="B6">
          <title>Sym023 10.0 mg/kg</title>
          <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="B7">
          <title>Sym023 20.0 mg/kg</title>
          <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="7"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="64" upper_limit="64"/>
                    <measurement group_id="B2" value="64" lower_limit="64" upper_limit="64"/>
                    <measurement group_id="B3" value="62" lower_limit="59" upper_limit="67"/>
                    <measurement group_id="B4" value="66" lower_limit="45" upper_limit="70"/>
                    <measurement group_id="B5" value="71" lower_limit="59" upper_limit="72"/>
                    <measurement group_id="B6" value="54" lower_limit="37" upper_limit="76"/>
                    <measurement group_id="B7" value="61" lower_limit="36" upper_limit="74"/>
                    <measurement group_id="B8" value="63" lower_limit="36" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG PS</title>
          <description>The ECOG PS is Eastern Cooperative Oncology Group performance status, and is a measure of how well a person is able to carry out ordinary daily activities while living with cancer, and provides an estimate of what treatments a person may tolerate. It has scores ranging from 0 to 5 with 0 being best and 5 being worst. ECOG is commonly used as a prognostic tool, as a selection criterion for cancer research, and to help determine treatment. Patients with an ECOG PS of 0 or 1 were included in the trial.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Treatment Emergent Adverse Events (AEs) Meeting Dose-limiting Toxicity (DLT) Criteria.</title>
        <description>Assess the safety and tolerability of Sym023 on a Q2W (once every 2 weeks) schedule to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1. The MTD was to be determined by those DLTs that occurred during C1 in either more than 1 patient in a 3 to 6 patient cohort or ≥33.3% of patients in the event of an expanded 7 to 12 patient cohort. One patient in the 10.0 mg/kg dose cohort was not evaluable for MTD as she did not complete C1 for a reason other than drug toxicity (i.e., discontinuation after 1 dose due to patient withdrawal of consent). However, this patient was included in the evaluation of other outcomes.</description>
        <time_frame>28 days</time_frame>
        <population>DLT analysis set of patients who completed treatment dosing in a 4-week (28 day) period that was Cycle 1. One patient out of 7 patients in Group 10mg/kg did not complete Cycle 1 and are not included in the &quot;participants analyzed&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Sym023 0.03 mg/kg</title>
            <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sym023 0.1 mg/kg</title>
            <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sym023 0.3 mg/kg</title>
            <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Sym023 1.0 mg/kg</title>
            <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Sym023 3.0 mg/kg</title>
            <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Sym023 10.0 mg/kg</title>
            <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O7">
            <title>Sym023 20.0 mg/kg</title>
            <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Treatment Emergent Adverse Events (AEs) Meeting Dose-limiting Toxicity (DLT) Criteria.</title>
          <description>Assess the safety and tolerability of Sym023 on a Q2W (once every 2 weeks) schedule to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1. The MTD was to be determined by those DLTs that occurred during C1 in either more than 1 patient in a 3 to 6 patient cohort or ≥33.3% of patients in the event of an expanded 7 to 12 patient cohort. One patient in the 10.0 mg/kg dose cohort was not evaluable for MTD as she did not complete C1 for a reason other than drug toxicity (i.e., discontinuation after 1 dose due to patient withdrawal of consent). However, this patient was included in the evaluation of other outcomes.</description>
          <population>DLT analysis set of patients who completed treatment dosing in a 4-week (28 day) period that was Cycle 1. One patient out of 7 patients in Group 10mg/kg did not complete Cycle 1 and are not included in the &quot;participants analyzed&quot;</population>
          <units>Number of DLTs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Immunogenicity of Sym023.</title>
        <description>Serum sampling to assess the potential for anti-drug antibody (ADA) formation. The number of patients with positive samples at indicated visits is presented.</description>
        <time_frame>Baseline up to 6-months follow-up, approximately 1 year</time_frame>
        <population>Full analysis set of all randomised and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Sym023 0.03 mg/kg</title>
            <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sym023 0.1 mg/kg</title>
            <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sym023 0.3 mg/kg</title>
            <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Sym023 1.0 mg/kg</title>
            <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Sym023 3.0 mg/kg</title>
            <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Sym023 10.0 mg/kg</title>
            <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O7">
            <title>Sym023 20.0 mg/kg</title>
            <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Immunogenicity of Sym023.</title>
          <description>Serum sampling to assess the potential for anti-drug antibody (ADA) formation. The number of patients with positive samples at indicated visits is presented.</description>
          <population>Full analysis set of all randomised and treated patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 days 1 and 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 days 1 and 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 days 1 and 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-month follow up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-month follow up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Objective Response (OR) or Stable Disease (SD) by RECIST v1.1</title>
        <description>OR or SD Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). The number of patients with confirmed or unconfirmed OR (partial or complete response) is presented. Duration of SD for patients with best overall response = SD was defined as the time from the day of first study treatment to the start of radiologic disease progression or death. If the patient did not have a radiological disease progression or death, the duration of SD was defined as the time from the day of first study treatment to the date of the last SD assessment.</description>
        <time_frame>24 months</time_frame>
        <population>Full analysis set of randomised and treated patients who was evaluable for response. One patient out of 7 in group 10mg/kg was not evaluable for response</population>
        <group_list>
          <group group_id="O1">
            <title>Sym023 0.03 mg/kg</title>
            <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sym023 0.1 mg/kg</title>
            <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sym023 0.3 mg/kg</title>
            <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Sym023 1.0 mg/kg</title>
            <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Sym023 3.0 mg/kg</title>
            <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Sym023 10.0 mg/kg</title>
            <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O7">
            <title>Sym023 20.0 mg/kg</title>
            <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Objective Response (OR) or Stable Disease (SD) by RECIST v1.1</title>
          <description>OR or SD Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). The number of patients with confirmed or unconfirmed OR (partial or complete response) is presented. Duration of SD for patients with best overall response = SD was defined as the time from the day of first study treatment to the start of radiologic disease progression or death. If the patient did not have a radiological disease progression or death, the duration of SD was defined as the time from the day of first study treatment to the date of the last SD assessment.</description>
          <population>Full analysis set of randomised and treated patients who was evaluable for response. One patient out of 7 in group 10mg/kg was not evaluable for response</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OR rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD &gt;16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD ≤16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Objective Response (OR) or Stable Disease (SD) by iRECIST</title>
        <description>OR or SD Assessed by Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST). The number of patients with confirmed or unconfirmed OR (partial or complete response) is presented. Duration of SD for patients with best overall response = SD was defined as the time from the day of first study treatment to the start of radiologic disease progression or death. If the patient did not have a radiological disease progression or death, the duration of SD was defined as the time from the day of first study treatment to the date of the last SD assessment.</description>
        <time_frame>24 months</time_frame>
        <population>Full analysis set of randomised and treated patients who were evaluable for response. One patient out of 7 in group 10mg/kg was not evaluable for response</population>
        <group_list>
          <group group_id="O1">
            <title>Sym023 0.03 mg/kg</title>
            <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sym023 0.1 mg/kg</title>
            <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sym023 0.3 mg/kg</title>
            <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Sym023 1.0 mg/kg</title>
            <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Sym023 3.0 mg/kg</title>
            <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Sym023 10.0 mg/kg</title>
            <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O7">
            <title>Sym023 20.0 mg/kg</title>
            <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Objective Response (OR) or Stable Disease (SD) by iRECIST</title>
          <description>OR or SD Assessed by Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST). The number of patients with confirmed or unconfirmed OR (partial or complete response) is presented. Duration of SD for patients with best overall response = SD was defined as the time from the day of first study treatment to the start of radiologic disease progression or death. If the patient did not have a radiological disease progression or death, the duration of SD was defined as the time from the day of first study treatment to the date of the last SD assessment.</description>
          <population>Full analysis set of randomised and treated patients who were evaluable for response. One patient out of 7 in group 10mg/kg was not evaluable for response</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OR rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>iSD &gt;16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>iSD ≤16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Objective Response (OR) or Stable Disease (SD) by RECIL 2017.</title>
        <description>OR or SD Assessed by Response Evaluation Criteria in Lymphomas 2017 (RECIL 2017)</description>
        <time_frame>24 months</time_frame>
        <population>No lymphomas were recorded in this trial, therefore it was not possible to do the RECIL evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Sym023 0.03 mg/kg</title>
            <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sym023 0.1 mg/kg</title>
            <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sym023 0.3 mg/kg</title>
            <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Sym023 1.0 mg/kg</title>
            <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Sym023 3.0 mg/kg</title>
            <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Sym023 10.0 mg/kg</title>
            <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O7">
            <title>Sym023 20.0 mg/kg</title>
            <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Objective Response (OR) or Stable Disease (SD) by RECIL 2017.</title>
          <description>OR or SD Assessed by Response Evaluation Criteria in Lymphomas 2017 (RECIL 2017)</description>
          <population>No lymphomas were recorded in this trial, therefore it was not possible to do the RECIL evaluation.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP) of Disease.</title>
        <description>Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1, RECIL 2017, or iRECIST, depending on tumor type. The numbers shown below correspond to the values related to RECIST v1.1.</description>
        <time_frame>24 months</time_frame>
        <population>The full analysis set of randomized and treated patients who were evaluable for response. One patient out of 7 in group 10mg/kg was not evaluable for response or time to progression (TTP) as the patient left trial due to Adverse Event</population>
        <group_list>
          <group group_id="O1">
            <title>Sym023 0.03 mg/kg</title>
            <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sym023 0.1 mg/kg</title>
            <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sym023 0.3 mg/kg</title>
            <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Sym023 1.0 mg/kg</title>
            <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Sym023 3.0 mg/kg</title>
            <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Sym023 10.0 mg/kg</title>
            <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O7">
            <title>Sym023 20.0 mg/kg</title>
            <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP) of Disease.</title>
          <description>Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1, RECIL 2017, or iRECIST, depending on tumor type. The numbers shown below correspond to the values related to RECIST v1.1.</description>
          <population>The full analysis set of randomized and treated patients who were evaluable for response. One patient out of 7 in group 10mg/kg was not evaluable for response or time to progression (TTP) as the patient left trial due to Adverse Event</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" lower_limit="1.81" upper_limit="1.81"/>
                    <measurement group_id="O2" value="7.89" lower_limit="7.89" upper_limit="7.89"/>
                    <measurement group_id="O3" value="1.18" lower_limit="0.72" upper_limit="1.38"/>
                    <measurement group_id="O4" value="3.48" lower_limit="1.87" upper_limit="3.55"/>
                    <measurement group_id="O5" value="1.28" lower_limit="1.12" upper_limit="3.52"/>
                    <measurement group_id="O6" value="1.68" lower_limit="0.03" upper_limit="2.07"/>
                    <measurement group_id="O7" value="5.36" lower_limit="1.61" upper_limit="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve in a Dosing Interval (AUC).</title>
        <description>The AUC after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
        <time_frame>From before the start of the infusion to 168 hours after the end of the infusion</time_frame>
        <population>Pharmacokinetic analysis set (same as the full analysis set) of all randomised and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Sym023 0.03 mg/kg</title>
            <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sym023 0.1 mg/kg</title>
            <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sym023 0.3 mg/kg</title>
            <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Sym023 1.0 mg/kg</title>
            <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Sym023 3.0 mg/kg</title>
            <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Sym023 10.0 mg/kg</title>
            <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O7">
            <title>Sym023 20.0 mg/kg</title>
            <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve in a Dosing Interval (AUC).</title>
          <description>The AUC after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
          <population>Pharmacokinetic analysis set (same as the full analysis set) of all randomised and treated patients</population>
          <units>h*μg/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="70" upper_limit="70"/>
                    <measurement group_id="O2" value="176" lower_limit="176" upper_limit="176"/>
                    <measurement group_id="O3" value="878" lower_limit="680" upper_limit="1158"/>
                    <measurement group_id="O4" value="3193" lower_limit="2449" upper_limit="4194"/>
                    <measurement group_id="O5" value="8062" lower_limit="4498" upper_limit="12358"/>
                    <measurement group_id="O6" value="30581" lower_limit="7039" upper_limit="45928"/>
                    <measurement group_id="O7" value="77262" lower_limit="54275" upper_limit="85463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax)</title>
        <description>Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
        <time_frame>From before the start of the infusion to 168 hours after the end of the infusion</time_frame>
        <population>Pharmacokinetic analysis set (same as the full analysis set) of all randomised and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Sym023 0.03 mg/kg</title>
            <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sym023 0.1 mg/kg</title>
            <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sym023 0.3 mg/kg</title>
            <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Sym023 1.0 mg/kg</title>
            <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Sym023 3.0 mg/kg</title>
            <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Sym023 10.0 mg/kg</title>
            <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O7">
            <title>Sym023 20.0 mg/kg</title>
            <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax)</title>
          <description>Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
          <population>Pharmacokinetic analysis set (same as the full analysis set) of all randomised and treated patients</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.85" upper_limit="0.85"/>
                    <measurement group_id="O2" value="1.98" lower_limit="1.98" upper_limit="1.98"/>
                    <measurement group_id="O3" value="7.94" lower_limit="5.67" upper_limit="11.56"/>
                    <measurement group_id="O4" value="23.71" lower_limit="19.87" upper_limit="28.30"/>
                    <measurement group_id="O5" value="68.03" lower_limit="52.88" upper_limit="84.16"/>
                    <measurement group_id="O6" value="232.11" lower_limit="183.26" upper_limit="288.01"/>
                    <measurement group_id="O7" value="470.24" lower_limit="294.82" upper_limit="543.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Concentration (Tmax)</title>
        <description>Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
        <time_frame>From before the start of the infusion to 168 hours after the end of the infusion</time_frame>
        <population>Pharmacokinetic analysis set (same as the full analysis set) of all randomised and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Sym023 0.03 mg/kg</title>
            <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sym023 0.1 mg/kg</title>
            <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sym023 0.3 mg/kg</title>
            <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Sym023 1.0 mg/kg</title>
            <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Sym023 3.0 mg/kg</title>
            <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Sym023 10.0 mg/kg</title>
            <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O7">
            <title>Sym023 20.0 mg/kg</title>
            <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Concentration (Tmax)</title>
          <description>Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
          <population>Pharmacokinetic analysis set (same as the full analysis set) of all randomised and treated patients</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="4.5" upper_limit="4.5"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.6" upper_limit="0.6"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.5" upper_limit="2.5"/>
                    <measurement group_id="O4" value="4.5" lower_limit="4.4" upper_limit="4.7"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.6" upper_limit="2.6"/>
                    <measurement group_id="O6" value="3.4" lower_limit="0.5" upper_limit="8.5"/>
                    <measurement group_id="O7" value="7.3" lower_limit="0.5" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Concentration (Ctrough)</title>
        <description>Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
        <time_frame>From before the start of the infusion to 168 hours after the end of the infusion</time_frame>
        <population>Pharmacokinetic analysis set (same as the full analysis set) of all randomized and treated patients. Data for cohort 0.03mg/kg: Ctrough at 168 hours were below the limit of quantification, hence no reported data</population>
        <group_list>
          <group group_id="O1">
            <title>Sym023 0.03 mg/kg</title>
            <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sym023 0.1 mg/kg</title>
            <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sym023 0.3 mg/kg</title>
            <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Sym023 1.0 mg/kg</title>
            <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Sym023 3.0 mg/kg</title>
            <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Sym023 10.0 mg/kg</title>
            <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O7">
            <title>Sym023 20.0 mg/kg</title>
            <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Concentration (Ctrough)</title>
          <description>Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
          <population>Pharmacokinetic analysis set (same as the full analysis set) of all randomized and treated patients. Data for cohort 0.03mg/kg: Ctrough at 168 hours were below the limit of quantification, hence no reported data</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Ctrough at 168 hours were below the limit of quantification, hence no reported data</measurement>
                    <measurement group_id="O2" value="0.16" lower_limit="0.16" upper_limit="0.16"/>
                    <measurement group_id="O3" value="1.26" lower_limit="0.76" upper_limit="1.85"/>
                    <measurement group_id="O4" value="6.39" lower_limit="4.26" upper_limit="9.37"/>
                    <measurement group_id="O5" value="12.88" lower_limit="4.09" upper_limit="26.10"/>
                    <measurement group_id="O6" value="74.33" lower_limit="37.47" upper_limit="116.52"/>
                    <measurement group_id="O7" value="146.96" lower_limit="101.68" upper_limit="189.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (T½)</title>
        <description>Outcome measure after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
        <time_frame>From before the start of the infusion to 168 hours after the end of the infusion</time_frame>
        <population>Pharmacokinetic analysis set (same as the full analysis set) of all randomised and treated patients. Data for cohort 0.03mg/kg: T½ could not be accurately calculated due to few datapoint within the elimination period</population>
        <group_list>
          <group group_id="O1">
            <title>Sym023 0.03 mg/kg</title>
            <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sym023 0.1 mg/kg</title>
            <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sym023 0.3 mg/kg</title>
            <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Sym023 1.0 mg/kg</title>
            <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Sym023 3.0 mg/kg</title>
            <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Sym023 10.0 mg/kg</title>
            <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O7">
            <title>Sym023 20.0 mg/kg</title>
            <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (T½)</title>
          <description>Outcome measure after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
          <population>Pharmacokinetic analysis set (same as the full analysis set) of all randomised and treated patients. Data for cohort 0.03mg/kg: T½ could not be accurately calculated due to few datapoint within the elimination period</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">T½ could not be accurately calculated due to few datapoints within the elimination</measurement>
                    <measurement group_id="O2" value="105.10" lower_limit="105.10" upper_limit="105.10"/>
                    <measurement group_id="O3" value="153.49" lower_limit="136.70" upper_limit="164.11"/>
                    <measurement group_id="O5" value="140.60" lower_limit="112.78" upper_limit="168.42"/>
                    <measurement group_id="O6" value="185.22" lower_limit="153.43" upper_limit="217.01"/>
                    <measurement group_id="O7" value="203.07" lower_limit="203.07" upper_limit="203.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (CL)</title>
        <description>Outcome measure after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
        <time_frame>From before the start of the infusion to 168 hours after the end of the infusion</time_frame>
        <population>Pharmacokinetic analysis set (same as the full analysis set) of all randomized and treated patients. Data for cohort 0.03mg/kg: Clearence could not be accurately calculated since too few datapoint within the elimination period</population>
        <group_list>
          <group group_id="O1">
            <title>Sym023 0.03 mg/kg</title>
            <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sym023 0.1 mg/kg</title>
            <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sym023 0.3 mg/kg</title>
            <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Sym023 1.0 mg/kg</title>
            <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Sym023 3.0 mg/kg</title>
            <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Sym023 10.0 mg/kg</title>
            <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
          <group group_id="O7">
            <title>Sym023 20.0 mg/kg</title>
            <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL)</title>
          <description>Outcome measure after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.</description>
          <population>Pharmacokinetic analysis set (same as the full analysis set) of all randomized and treated patients. Data for cohort 0.03mg/kg: Clearence could not be accurately calculated since too few datapoint within the elimination period</population>
          <units>mL/h)/kg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.501" lower_limit="0.501" upper_limit="0.501"/>
                    <measurement group_id="O3" value="0.364" lower_limit="0.364" upper_limit="0.364"/>
                    <measurement group_id="O5" value="0.582" lower_limit="0.582" upper_limit="0.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>Only treatment-emergent adverse events (AEs) are presented in clinicaltrials.gov, defined as AEs with onset dates on or after the first dose of study medication or AEs that occurred before the first dose of study medication and increased in severity after the first dose of study medication up to the last dose of study drug plus 30 days.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sym023 0.03 mg/kg</title>
          <description>Sym023 0.03 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Sym023 0.1 mg/kg</title>
          <description>Sym023 0.1 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>Sym023 0.3 mg/kg</title>
          <description>Sym023 0.3 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="E4">
          <title>Sym023 1.0 mg/kg</title>
          <description>Sym023 1.0 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="E5">
          <title>Sym023 3.0 mg/kg</title>
          <description>Sym023 3.0 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="E6">
          <title>Sym023 10.0 mg/kg</title>
          <description>Sym023 10.0 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
        <group group_id="E7">
          <title>Sym023 20.0 mg/kg</title>
          <description>Sym023 20.0 mg/kg intravenous infusion once every 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Immune-mediated arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Symphogen AS</organization>
      <phone>0045 45265050</phone>
      <email>info@symphogen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

